pain management

Avenue Therapeutics Inc (NASDAQ: ATXI) announced the outcome of the FDA meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol. The Advisory Committee had to vote on "has the Applicant submitted...

Medtronic plc (NYSE: MDT) announced three-month results from an on-label, prospective, multi-center study of Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS) pain therapy. The data showed meaningful pain relief using DTM SCS endurance therapy for chronic overall,...

Mesoblast Limited (NASDAQ: MESO) received feedback from the FDA's Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients. The trial is assessing rexlemestrocel-L in patients with chronic low back pain (CLBP) due to degenerative...

The FDA has approved expanded labeling for Cumberland Pharmaceuticals Inc's (NASDAQ: CPIX) Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration.  The non-narcotic pain reliever can now be administered just...

iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc (NASDAQ: SEEL). Seelos will have exclusive worldwide rights for Wafermine, except China, including Hong Kong, Macau, and Taiwan - for which iX...

Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs. PNV-5030 has been tested...

The FDA has given 510(k) clearance to Venus Concept Inc's (NASDAQ: VERO) Venus Freedom device for pain management. Venus Freedom is a noninvasive, non-ablative device with three applicators to deliver non-thermal radiofrequency energy combined with massage and magnetic...

NanoVibronix Inc (NASDAQ: NAOV) has announced results from a randomized, double-blind study to evaluate the safety and effectiveness of the NanoVibronix PainShield. Related: NanoVibronix Launches CBD-Based Product For Pain Management. Patients in the study were being treated by...

Flexion Therapeutics Inc (NASDAQ: FLXN) expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy.  Related: Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery. FX301 is a formulation of a locally administered NaV1.7...

NanoVibronix Inc (NASDAQ: NAOV) plans to enter the Over-the-Counter (OTC) pain relief market by introducing PainShield RELIEF, a non-prescription ultrasound therapy device. Brian Murphy, Chief Executive Officer, commented, "Entering the OTC pain relief market with our newest...

A day after Trevena Inc (NASDAQ: TRVN) shares suffered a setback in reaction to a FDA committe's briefing document, another stock is trading higher following the release of a briefing document pertaining to its adcom review. What Happened The briefing document released by FDA's...

Shares of Cara Therapeutics Inc (NASDAQ: CARA), a small-cap clinical-stage bio-pharmaceutical company that develops therapies to alleviate pain, gained more than 15 percent early Tuesday morning after the company announced encouraging results from Part A of a Phase 2/3 trial. Cara has been...

Egalet Corp (NASDAQ: EGLT) is a U.S.-based specialty pharmaceutical company that focus on treatments for pain and other conditions. The company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. Benzinga had the privilege of chatting with the company...